Sign up
Pharma Capital

Orgenesis' cell therapy development business pushes into the US

Orgenesis Inc (NASDAQ:ORGS) CEO Vered Caplan and General Manager Ohad Karnieli tells Proactive Investor's Christine Corrado the vertically-integrated biopharmaceutical company is developing cost-efficient cell therapies to bring to the market.

Caplan and Karnieli say the company is expanding its service business in the US, and have already engaged with various US listed, European, and Asian based clients. The company is looking forward to this expansion activity into wider geographical areas so that it may serve additional US and non-US companies.

 

View full ORGS profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.